Whilst negative PD-L1 TPS < 1% is associated with a lesser benefit for single agent anti-PD-(L)1 therapy, around 10% of patients with advanced NSCLC and PD-L1 TPS < 1% may still demonstrate an objective and durable response [2]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.